treprostinil (Tyvaso, Unipros, Remodulin, Senicopac, Orenitram)
Jump to navigation
Jump to search
Indications
- treatment of pulmonary arterial hypertension, including when due to interstitial lung disease[2]
Dosage
- for inhalation, 1-3 inhalations QID
- administer undiluted, as supplied
- a single inhalation of Tyvaso delivers ~6 mcg of treprostinil
Sterile solution for oral inhalation:
Pharmacokinetics
Adverse effects
- most common adverse reactions (>10%)
- syncope (6%)
- may cause acute bronchospasm
- Postmarketing reports
Drug interactions
- concomitant diuretics, antihypertensives or other vasodilators may increase the risk of hypotension
Mechanism of action
More general terms
References
- ↑ Prescriber's Letter 17(2): 2010 New Drugs Approved by the FDA in 2009 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260213&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 2.0 2.1 Waxman A, Restrepo-Jaramillo R, Thenappan T et al Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med 2021. Jan 13, PMID: https://www.ncbi.nlm.nih.gov/pubmed/33440084 https://www.nejm.org/doi/full/10.1056/NEJMoa2008470
Taichman DB Optimism for Interstitial Lung Disease-Associated Pulmonary Hypertension? N Engl J Med 2021. Jan 13, PMID: https://www.ncbi.nlm.nih.gov/pubmed/33440083 https://www.nejm.org/doi/full/10.1056/NEJMe2033181 - ↑ Medscape: treprostinil inhaled (Rx) https://reference.medscape.com/drug/tyvaso-tyvaso-dpi-treprostinil-inhaled-4000061
Database
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=54786
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6918140
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11246284
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9800580
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=23699700
- PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=23663413